Skip to main content

Profiling Responders In Antibody Therapies

Objective

"Therapeutic antibodies are the largest and fastest growing class of pharmaceutical biotechnology products, with annual sales above 30 billion US$. In some cases, antibody products have revolutionized the management of patients, e.g. TNF-blocking antibodies in Arthritis or Rituxan in lymphoma. However, for most antibody therapies, only a subset of patients benefit from treatment. Thus, there is an urgent need to develop more potent therapeutic antibodies and to understand the molecular basis for the differential responses of patients to treatment.
This consortium consists of European centres of excellence being pioneers in the field of therapeutic antibody development and (pre-) clinical studies and will tackle both of these challenges:
Innovative immunocytokines L19-IL2 and F8-IL10 are developed by Philogen for the treatment of metastatic melanoma and rheumatoid arthritis respectively at multiple clinical centres including Graz and Tübingen.
Building on the strong background in proteomics biomarker discovery of ETH Zurich and Philochem, an innovative methodology (“HLA-peptidome analysis”) will be utilized for gaining information on the immune response in animal models and patients which receive antibody treatments. This method is based on the observation that HLA molecules in complex with peptides can be detected in the patient blood and that hundreds of HLA-associated peptides can be sequenced by mass spectrometry. The technology will be used for the profiling of responses following antibody treatment for patients with cancer and rheumatoid arthritis, as well as animal models of transplant rejection. This systems biology approach has the potential to revolutionize patient stratification in very short time.
Finally, patient selection strategies will be investigated using the clinical-grade immunocytokine (F8-IL10) as an example, monitoring antibody uptake at the site of disease by immuno-PET imaging methodologies at VUMC Amsterdam in collaboration with Philogen."

Call for proposal

FP7-HEALTH-2012-INNOVATION-1
See other projects for this call

Coordinator

EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH
Address
Raemistrasse 101
8092 Zuerich
Switzerland
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 539 987
Administrative Contact
Dario Neri (Prof.)

Participants (7)

PHILOGEN SPA
Italy
EU contribution
€ 304 980
Address
Piazza La Lizza 7
53100 Siena
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Chiara Falciani (Dr.)
PHILOCHEM AG
Switzerland
EU contribution
€ 755 028
Address
Wolfgang Pauli Strasse 10
8093 Zurich
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Tim Fugmann (Dr.)
STICHTING VU
Netherlands
EU contribution
€ 383 034
Address
De Boelelaan 1105
1081 HV Amsterdam
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Gerard Hoskens (Dr.)
UNIVERSITATSKLINIKUM JENA
Germany
EU contribution
€ 286 260
Address
Kastanienstr.1
07747 Jena
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Marcus Franz (Dr.)
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Germany
EU contribution
€ 206 460
Address
Geschwister-scholl-platz
72074 Tuebingen
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Claus Garbe (Prof.)
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
United Kingdom
EU contribution
€ 285 276
Address
Wellington Square University Offices
OX1 2JD Oxford
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Linda Pialek (Ms.)
MEDIZINISCHE UNIVERSITAT GRAZ
Austria
EU contribution
€ 206 460
Address
Auenbruggerplatz 2
8036 Graz
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Thomas Korenjak (Mr.)